GLP-1 Drugs and Eye Health: AAO 2025 Findings
GLP-1 Drugs and Eye Health: A Mixed Bag of Findings from AAO 2023
Recent research presented at the American Academy of Ophthalmology (AAO) 2023 meeting is shedding light on the complex relationship between GLP-1 receptor agonists (like semaglutide and tirzepatide), used for weight loss and diabetes management, and various eye conditions. The findings are somewhat contradictory, suggesting different effects on different diseases.
Here’s a breakdown of the key takeaways:
* Diabetic Retinopathy: A study published in Ophthalmology Science in November/December 2024 found no worsening of diabetic retinopathy with GLP-1 drugs.
* Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) & Diabetic Retinopathy: Analysis of data from over 117,000 diabetic patients showed that those using semaglutide were significantly more likely to develop NAION (68.6x higher risk) and diabetic retinopathy (8x higher risk) compared to those taking empagliflozin, exenatide, insulin, or metformin. Tirzepatide showed no significant association with either condition.
* Age-Related Macular Degeneration (AMD): A study of over 430,000 diabetic patients aged 50+ found that GLP-1 use was associated with a lower risk of developing dry AMD. Specifically, patients taking a GLP-1 for five years had:
* 63% lower risk than those on metformin
* 58% lower risk than those on insulin
* 54% lower risk than those on SGLT2i
* Wet AMD: The study found no significant protection against the wet form of AMD.
In essence: The data suggests that different GLP-1 drugs may have varying effects on eye health. Semaglutide appears to carry a higher risk for NAION and diabetic retinopathy, while GLP-1s as a class may offer some protection against dry AMD. Tirzepatide doesn’t seem to have the same risks as semaglutide regarding NAION and diabetic retinopathy.
It’s significant to note that these are observational studies and further research is needed to confirm these findings and understand the underlying mechanisms.
[Image of Moiz Lakhani] (This image was referenced in the original text but not provided in the prompt.)